Physician profile
Sherry E Coffield
NPI 1750552014
$4,377.13
in general payments reported to CMS, 2019-2025
22 companies · $681 in 2025
The $681 reported for 2025 was more than what 78% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $583 · 2022: $730 · 2023: $1,134 · 2024: $1,248 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.86 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $730.66 | 2021-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $536.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $442.94 | 2022-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $436.81 | 2023-2025 | |
| Abbvie INC. | $349.18 | 2021-2024 | |
| Astellas Pharma US INC | $290.07 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $281.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $213.63 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $210.79 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.58 | 2021-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $167.92 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $93.42 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $76.26 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $63.23 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.17 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $49.96 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Xeris Pharmaceuticals, INC. | $40.73 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $35.76 | 2023-2024 | Trelegy Ellipta, Bexsero, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.17 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $27.11 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $19.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Coffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.